Total Androgen Blockade Versus a Luteinizing Hormone–Releasing Hormone Agonist Alone in Men With High-Risk Prostate Cancer Treated With Radiotherapy
A Nanda, MH Chen, BJ Moran, MH Braccioforte… - International Journal of …, 2010 - Elsevier
PURPOSE: To assess whether short-course total androgen blockade vs. a luteinizing
hormone–releasing hormone (LHRH) agonist alone affects the risk of prostate cancer–
specific mortality (PCSM) in men with localized but high-risk disease treated with
radiotherapy. METHODS AND MATERIALS: The study cohort comprised 628 men with T1–
T4, N0, M0 prostate cancer with high-risk disease (prostate-specific antigen level> 20 ng/mL,
Gleason score≥ 8, or clinical category≥ T3) treated with 45 Gy of external beam …
hormone–releasing hormone (LHRH) agonist alone affects the risk of prostate cancer–
specific mortality (PCSM) in men with localized but high-risk disease treated with
radiotherapy. METHODS AND MATERIALS: The study cohort comprised 628 men with T1–
T4, N0, M0 prostate cancer with high-risk disease (prostate-specific antigen level> 20 ng/mL,
Gleason score≥ 8, or clinical category≥ T3) treated with 45 Gy of external beam …